Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis

Andō, Koichi; Manabe, Ryo; Kishino, Yasunari; Kusumoto, Sojiro; Yamaoka, Toshimitsu; Tanaka, Akihiko; Ohmori, Tohru; Sagara, Hironori

doi:10.3390/cancers13153704

Public

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis

Published in Cancers • Jul 23, 2021

Authors:

Koichi Andō

Ryo Manabe

Yasunari Kishino

Abstract

To date, there have been no head-to-head randomized controlled trials (RCTs) comparing the safety and efficacy of lorlatinib and alectinib in anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) ALK-inhibitor‒naïve advanced non-small cell lung cancer (NSCLC). We performed a network meta-a...

Subject

Alectinib

Crizotinib

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!